Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR 1,151.80
-19.15 (-1.64%)
Feb 21, 2025, 3:29 PM IST
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 83.59B INR in the quarter ending December 31, 2024, with 15.85% growth. This brings the company's revenue in the last twelve months to 311.31B, up 14.74% year-over-year. In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of 279.16B with 13.54% growth.
Revenue (ttm)
311.31B
Revenue Growth
+14.74%
P/S Ratio
n/a
Revenue / Employee
11.51M
Employees
27,048
Market Cap
959.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | 174.60B | 20.75B | 13.49% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Dr. Reddy's Laboratories News
- 3 days ago - Nifty 50 top losers today on February 19: Dr. Reddy’s Laboratories, TCS, Infosys and Hindustan Unilever - Business Upturn
- 16 days ago - Dr Reddy’s inks exclusive deal for cancer drug in US, EU - The Times of India
- 16 days ago - Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy - Seeking Alpha
- 16 days ago - Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire
- 16 days ago - Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. - PRNewsWire
- 16 days ago - Dr. Reddy’s signs $131.6 million deal with Henlius to commercialize multiple myeloma biosimilar in US and Europe - Business Upturn
- 16 days ago - Nifty 50 top gainers today on February 6: Cipla, ITC Hotels, Dr. Reddy’s Laboratories, HDFC Life and more - Business Upturn
- 23 days ago - Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns - Seeking Alpha